Beijing KeyGen Gene Technology

Beijing KeyGen Gene Technology is a China-based life science company focused on the research, production, and sale of biologic raw materials for in vitro diagnostics, while also conducting early innovative drug work in monoclonal antibodies and antibody-drug conjugates. The company has built technical capabilities spanning gene recombination, protein expression and purification, hybridoma, and engineered antibody expression. Its commercial emphasis appears to be supplying bioactive protein and antibody reagents and providing related research services, with disease coverage including infectious disease, oncology, cardiovascular, and related diagnostic applications. In 2024, Beijing Hotgen Biotech acquired 100% of the company, and KeyGen now operates as a subsidiary within Hotgen's diagnostics-focused group structure. Publicly visible evidence supports platform and raw-material capabilities, but only limited disclosure is available on a named therapeutic pipeline.